Company profile: eNeura
1.1 - Company Overview
Company description
- Provider of non-invasive single-pulse transcranial magnetic stimulation (sTMS) devices and digital tools for migraine treatment and prevention, including the SAVI Dual Migraine Therapy device, SAVI Smart Diary for tracking treatment history and personalized patterns, and a dedicated support team for onboarding, optimizing results, monitoring progress, and managing prescription refills.
Products and services
- Dedicated SAVI Dual Support Team: Clinical team delivers customer care and support to initiate therapy, optimize outcomes, monitor progress, and coordinate prescription refills for migraine management
- SAVI Dual Migraine Therapy: Non-invasive device uses single-pulse transcranial magnetic stimulation (sTMS) to treat and prevent migraine attacks by calming hyperactive nerves in the brain
- SAVI Smart Diary: Cloud-based diary automatically records migraine treatment history and helps track personalized migraine patterns and treatment efficacy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to eNeura
Centrexion Therapeutics
HQ: United States
Website
- Description: Provider of late clinical-stage biopharmaceutical therapies for chronic pain, including CNTX-4975, a synthetic trans-capsaicin injected directly into the site of pain to treat moderate to severe knee osteoarthritis, targeting the TRPV1 receptor to selectively inactivate local pain fibers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Centrexion Therapeutics company profile →
Collegium Pharmaceutical
HQ: United States
Website
- Description: Provider of specialty pharmaceuticals for chronic pain, offering XTAMPZA ER (extended-release oxycodone for around-the-clock pain management), NUCYNTA ER (tapentadol for severe pain requiring daily, around-the-clock, long-term opioid treatment), NUCYNTA (tapentadol for moderate to severe acute pain in adults), BELBUCA (buprenorphine buccal film for long-term pain), and SYMPROIC (tablet for opioid-induced constipation in adults with chronic non-cancer pain).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Collegium Pharmaceutical company profile →
Durin Technologies
HQ: United States
Website
- Description: Provider of blood-based diagnostic tests and a multi-disease platform for neurodegenerative diseases, including Alzheimer’s and Parkinson’s, that detect disease-specific autoantibodies in serum for early detection and diagnosis, and for monitoring disease progression by tracking changes in autoantibody profiles over time.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Durin Technologies company profile →
Conformal Medical
HQ: United States
Website
- Description: Provider of transcatheter left atrial appendage occlusion solutions to prevent stroke in patients with nonvalvular atrial fibrillation, including the Conformal Left Atrial Appendage System (CLAAS) implant and the CONFORM clinical trial evaluating CLAAS versus other commercially available LAAO devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Conformal Medical company profile →
Phagenesis
HQ: United Kingdom
Website
- Description: Provider of neurostimulation solutions for dysphagia treatment, developing the Phagenyx System, which delivers Pharyngeal Electrical Stimulation to restore neurological control of swallowing. The system tailors stimulation to patient sensory capacity and uses a dual-function catheter for feeding and electrical therapy, harnessing neuroplasticity to improve safe swallowing in patients, including those post-stroke or with neuro-deficit diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phagenesis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for eNeura
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to eNeura
2.2 - Growth funds investing in similar companies to eNeura
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for eNeura
4.2 - Public trading comparable groups for eNeura
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →